The Top Life Science & Biotech Conferences to Attend in the U.S. in 2026

The 2026 biotech conferences calendar is one of the densest years biopharma and the broader life sciences industry have seen.

FDA approval velocity remains high. Inflation Reduction Act implementation is entering a more consequential phase. Generative AI is moving from R&D experimentation into operational deployment. And biotech investment trends point to a re-opening capital environment after a multi-year reset.

All of that translates into a packed year of events competing for commercial, R&D, investor, and executive attention.

The challenge for most life sciences teams isn’t finding a conference — it’s deciding which ones justify the registration, travel, and opportunity cost of pulling senior leaders out of the business. A well-chosen conference calendar helps a company accelerate science, connect directly with industry leaders, and identify the partnerships and pilot programs that ultimately improve lives.

To help, we’ve assembled the ten U.S.-based events most worth building into a 2026 plan, organized chronologically across the year.

Why 2026’s Conference Calendar Matters

The 2026 life sciences conference calendar spans the full commercial and scientific lifecycle. It runs from early investor partnerships at JPM Week in San Francisco through global biotechnology dealmaking in San Diego to the convergence of life sciences with digital health and AI innovation in the fall.

Networking is a central feature of every conference below, allowing attendees to connect with thousands of industry professionals, scientists, clinicians, and decision-makers.

Attending a well-chosen event offers each company opportunities to explore new partnerships, showcase solutions, and identify crucial investment opportunities. Major gatherings like the J.P. Morgan Healthcare Conference play a significant role in shaping industry conversations and trends, facilitating strategic deal-making among biotechnology leaders and investors.

Below are the ten events we’d put at the top of any serious 2026 life sciences list.

1. J.P. Morgan Healthcare Conference — January 12–15 | San Francisco, CA

The 44th J.P. Morgan Healthcare Conference opens the 2026 biopharma year and functions as the healthcare industry’s unofficial State of the Union.

Hosted at the Westin St. Francis in San Francisco, this invitation-only event is the premier annual gathering for the global health community. It’s designed to connect biotech executives, investors, and healthcare leaders for strategic deal-making and networking.

Over 8,000 attendees and more than 550 global healthcare companies are expected to attend in 2026, with a focus on new product launches, emerging technologies, AI-enabled drug discovery, and cell and gene therapy commercialization. The conference consistently sets the tone for product launches and biotech investment trends across the rest of the year.

Nearly 30 parallel conferences and private pitch events orbit the main stage during JPM Week, making it the epicenter of global healthcare deal-making.

Key participants include senior executives from major pharmaceutical companies, biotechnology innovators, institutional investors, and FDA and regulatory officials. For any company that needs investor visibility and partnership conversations in a single concentrated week, no other conference comes close.

2. Biotech Showcase — January 12–14 | San Francisco, CA

Running concurrently with J.P. Morgan, Biotech Showcase 2026 is the most structured investor conference of JPM Week.

Co-produced by Demy-Colton and Informa Connect at the Hilton Union Square, the conference adds digital partnering days on January 21–22. It’s purpose-built for the private and micro-to-mid-cap biotech companies that aren’t on the JPM main stage but still need serious investor exposure.

The 18th edition is expected to draw 3,200+ global biopharma professionals, including more than 1,200 investors and 350+ presenting companies. The partneringONE™ platform typically facilitates more than 6,000 one-on-one meetings during the event, with participating investors managing over $400B in aggregate capital.

Specialized tracks like TechBio Showcase and Seed Showcase give earlier-stage startups and founders a platform alongside later-stage presenters. Sessions also explore early-stage business development strategy and how to scale science and operations responsibly.

For any organization planning a 2026 financing round or BD conversations with crossover investors, Biotech Showcase registration frequently delivers stronger partnering ROI than any other event on the calendar.

3. AGBT General Meeting — February 23–26 | Orlando, FL

The Advances in Genome Biology and Technology (AGBT) General Meeting is the preeminent genome science and technology conference for leading global researchers and industry leaders.

Hosted by The Genome Partnership at the Signia by Hilton Orlando Bonnet Creek, the 2026 edition brings together more than 1,000 attendees from academia, biotech, and biopharma.

The conference’s focus spans cancer omics, informatics and computational biology, non-cancer medical and biological omics, and technology and application development. Heads of labs, institutions, businesses, and financial analysts converge to showcase new technologies, advance lab management practices, and discover the latest advances in sequencing and multiomics.

Evening concurrent sessions — AGBT’s signature format — focus on experimental and computational approaches that leverage the latest DNA sequencing technologies. Past talks have featured scientists from EMBL, the Chan Zuckerberg Biohub, Baylor College of Medicine, and the Broad Institute.

AGBT is particularly valuable for founders and companies developing genomics-enabled platforms, and for investors tracking emerging trends across sequencing, proteomics, and AI-driven genomics.

4. Reuters Events Pharma USA — March 16–17 | Philadelphia, PA

Reuters Events Pharma USA 2026, hosted at the Pennsylvania Convention Center, is the premier cross-functional conference for U.S. pharmaceutical commercial leadership.

Reuters positions the event as the largest North American gathering of biopharma professionals and decision-makers, with 1,500+ senior attendees across medical affairs, commercial, marketing, market access, data, and analytics functions.

The 2026 focus centers on patient-centric innovation, real world data strategies, generative AI in omnichannel engagement, launch excellence under IRA pressure, and the digital transformation of the commercial model.

Senior voices from GSK, Regeneron, Astellas, and Bristol Myers Squibb anchor the agenda. Sessions are designed to help attendees compare analytic approaches, showcase solutions, and exchange ideas across business functions.

For pharmaceutical organizations navigating IRA implementation and GLP-1 competitive dynamics, this conference is the agenda-setting event of the spring — particularly useful for cross-functional teams that want senior commercial, medical, and market access leaders in the same sessions.

5. AACR Annual Meeting — April 17–22 | San Diego, CA

The AACR Annual Meeting 2026 is the focal point of the cancer research community and one of the most scientifically rigorous conferences of the year.

Hosted at the San Diego Convention Center by the American Association for Cancer Research, the event gathers scientists, clinicians, other healthcare professionals, and patient advocates to share the latest advances in cancer science and medicine.

Programming spans population science and prevention, cancer biology, translational and clinical research, precision medicine, survivorship, and advocacy. More than 20,000 attendees are expected in 2026, with a focus on bridging research and clinical practice to improve outcomes for patients.

The exhibit floor showcases solutions across diagnostics, oncology drug development, biomarkers, AI-driven discovery, and clinical trial technologies — a compact view of where oncology science is heading.

For any company working at the intersection of oncology and precision medicine, AACR continues to advance the field and set the commercial direction for the year.

6. Asembia’s AXS26 Summit — April 26–30 | Las Vegas, NV

Asembia’s AXS26 Summit, held at the Wynn Las Vegas & Encore, is the preeminent convening of the specialty pharmacy and patient-access ecosystem.

Recent editions have drawn 8,000+ attendees from 1,400+ organizations, with 150+ speakers and a focus on the business of patient access.

The attendee mix is distinctive: specialty pharmacy executives, biopharma manufacturers, PBMs, health plans, wholesalers, patient hub services, and digital health companies. Programming has consistently led the industry on specialty pharmacy strategy, patient access and affordability, cell and gene therapy market access, biosimilars, AI in pharmacy operations, and policy implementation.

The 2026 general session will feature a fireside chat with Charlie Sheen — characteristic Asembia programming that blends cultural relevance with substantive industry conversations about real challenges in patient access.

For any company commercializing specialty, orphan, cell, or gene therapies, Asembia is the must-attend conference of the second quarter and arguably the most important venue for patient-access strategy on the U.S. calendar.

7. THMA Executive Forums — May 6–8 (Fort Lauderdale) & June 3–5 (Carlsbad, CA)

The Health Management Academy (THMA) operates a different kind of life sciences convening than the events above.

Rather than expo halls and 10,000-person crowds, THMA’s Executive Forums are retreat-style events with a strict 1:1 health system–to–industry ratio. They’re built for candid peer discussions between senior health system leaders and commercial teams, with a focus on the real challenges of commercial engagement.

Three THMA forums are particularly relevant for life sciences companies in 2026.

Oncology Forum

The Oncology Forum takes place May 6–8 in Fort Lauderdale and September 16–18 in Boston.

It connects senior oncology service line leaders directly with commercial and medical affairs teams around pathway governance, access execution, and operational adoption of complex therapies. Epomedicine recently named it among 2026’s top oncology conferences alongside ASCO and AACR.

Cardiovascular Forum

The Cardiovascular Forum takes place May 6–8 in Fort Lauderdale and September 16–18 in Boston.

The focus is service line strategy, site-of-care decisions, and formulary positioning for cardiovascular therapies — a pipeline category as active in 2026 as it has been in years.

Pharmacy Growth Collaborative

The Pharmacy Growth Collaborative takes place June 3–5 in Carlsbad, CA, and October 14–16 in Boston.

It connects health system pharmacy executives with commercial teams around formulary governance, 340B strategy, specialty drug access, and ambulatory infusion.

8. Bio-IT World Conference & Expo — May 19–21 | Boston, MA

The 25th annual Bio-IT World Conference & Expo is the most important cross-disciplinary event at the intersection of data, AI, and drug discovery.

Hosted at the Omni Boston Hotel at the Seaport, the 2026 edition is expected to draw 2,900+ attendees across 11 tracks and three symposia. The conference is organized by Cambridge Healthtech Institute, whose organizers have curated the agenda for 25 years.

The 2026 focus is on generative AI and machine learning in drug discovery, integrated informatics, computational biology, and intelligent lab systems. Topics include LLMs, knowledge graphs, FAIR data, quantum computing, and real-world operational deployment of AI across biopharma R&D environments.

Sessions highlight how pilot programs evolve into production, how companies showcase solutions that scale, and how new technologies are reshaping the life sciences ecosystem. Many talks focus on the operational challenges of moving AI from experimentation to execution.

For industry leaders operationalizing AI across the life sciences industry in 2026, Bio-IT World has become a must-attend expo on the conference calendar.

9. BIO International Convention — June 22–25 | San Diego, CA

The BIO International Convention is the largest and most comprehensive event for biotechnology, with approximately 21,500 industry leaders from around the world expected to attend in 2026.

Hosted at the San Diego Convention Center, the conference features 1,600+ exhibitors and 135+ sessions on biotechnology innovations, regulatory issues, and policy, with a focus on industry networking.

Attendees include C-suite biotech and biopharma executives, scientists, investors, regulators, policymakers, patient advocates, state and regional economic development organizations, and international trade delegations from 65+ countries. BIO Partnering™ facilitates tens of thousands of 1:1 meetings — more partnering volume than any other event globally.

Focus areas include next-generation biotherapeutics, cell and gene therapy, rare diseases, biomanufacturing, education, and the Start-Up Stadium pitch program for emerging founders. San Diego also provides natural convergence with the local innovation ecosystem of research institutions and biotechnology companies.

For any company seeking pharmaceutical partners, institutional investors, international market entry, or CDMO relationships, BIO International is the single best commercial development event of the year.

10. HLTH 2026 — November 15–18 | Las Vegas, NV

HLTH 2026 closes the 2026 calendar as the premier convergence conference for life sciences executives to connect with digital health, AI, and tech innovators.

Held at the Venetian Expo in Las Vegas, the event brings together 10,000+ attendees spanning health systems, payers, biopharma, biotech, and digital health startups. Registration opens to industry professionals across the commercial spectrum.

The 2026 edition features a dedicated Pharma & Life Sciences Zone, a Market Connect 1:1 meeting program for life sciences companies, a Startup Pitch Tournament, and a newly embedded Global Pharma Summit experience.

Programming spans generative AI and emerging technologies, diagnostics, women’s health, consumer health, and investor-facing discussions. HLTH is particularly valuable for commercial and digital innovation teams that want to explore how patient engagement, pilot programs, and new product launches are reshaping the launch model.

For startups, founders, and established life sciences companies alike, HLTH’s late-November timing makes it a useful final planning milestone before the JPM-driven start of 2027.

Building Your 2026 Life Sciences Conference Calendar

No single organization should attend all ten of these events. The right 2026 plan depends on function, stage, and strategic priority.

Early-stage biotech companies typically anchor around JPM Week and BIO International for capital formation and partnerships. Commercial teams get the most mileage from Reuters Events Pharma USA, Asembia, and executive forums like THMA’s. Genomics-focused companies should prioritize AGBT; oncology-focused teams, AACR.

Teams working to accelerate science through AI and data infrastructure should build around Bio-IT World. Digital-health-adjacent life sciences teams increasingly find HLTH to be the anchor event of the fall — and the best venue to explore what the future of commercial execution looks like.

What ties all ten conferences together is that they remain the highest-signal venues in their respective niches — where the right industry conversations are happening with the right people. Each event also provides access to the professionals, partnerships, and practices that will shape life sciences strategy for years to come.

If you haven’t locked in your 2026 conference calendar yet, these are the events worth starting with.